Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathogenic HER3 dimerization domain mutations create a structural bias towards un-conventional EGFR-HER3 signalling axis in breast cancer.

International journal of biological macromolecules - 1 Jul 2023

Dey Pranay, Gadewal Nikhil, De Abhijit

Abstract excerpt

Among the EGFR family of receptors, HER3 is considered as a pseudo-kinase which primarily interacts with HER2 in presence of heregulin-1β. We identified two hotspot mutations i.e. G284R and D297Y and one double mutant HER2-S310F/HER3-G284R in breast cancer patients. Long term MDS (7.5 μs) revealed that HER3-D297Y and HER2-S310F:HER3-G284R do not allow the interaction with HER2 as these mutations cause dramatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dimerization

Share to ErbB Receptors

Share to Mutation

Share to Neuregulin-1

Share to Receptor, ErbB-2

Share to Receptor, ErbB-3

Source

Identifiers

PMID: 37156315
DOI: 10.1016/j.ijbiomac.2023.124765

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathogenic HER3 dimerization domain mutations create a structural bias towards un-conventional EGFR-HER3 signalling axis in breast cancer.PMID 37156315Read ↗

HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of CancerSemantic proximity Read ↗

Activating HER3 mutations in breast cancerSemantic proximity Read ↗

Thirty Years of HER3: From Basic Biology to Therapeutic InterventionsSemantic proximity Read ↗

Molecular Pathways: HER3 Targeted TherapySemantic proximity Read ↗

HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer TherapySemantic proximity Read ↗

Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in breast Cancer: Therapeutic challenges and way forward.Semantic proximity Read ↗

Structures of the active HER2/HER3 receptor complex reveal dynamics at the dimerization interface induced by binding of a single ligandSemantic proximity Read ↗

Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failureSemantic proximity Read ↗

HER3/ErbB3, an emerging cancer therapeutic target.Semantic proximity Read ↗

Advances in Targeting HER3 as an Anticancer TherapySemantic proximity Read ↗

Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.